Selected publications

Publications - since 2016

• Development of new potential drugs with antimicrobial activity and cholinesterase inhibitors
• Development of new antituberculosis drugs
• Synthesis of dexrazoxane analogues and iron chelators

 

Development of new potential drugs with antimicrobial activity and cholinesterase inhibitors

2021

• Krátký M., Konečná K., Brokešová K., Maixnerová J., Trejtnar  F., Vinšová J. Optimizing the structure of (salicylideneamino)benzoic acids: Towards selective antifungal and anti-staphylococcal agents, Eur. J. Pharm. Sci. 2021, 159, 105732 [ISSN 0928-0987, IF₂₀₁₉ = 3.616]. https://doi.org.10.1016/j.ejps.2021.105732
• Y.Sheena Mary, Y.Shyma Mary, Krátký M., Vinsova J., Baraldi C., Gamberini M.C. Concentration dependent SERS, DFT and molecular docking studies of a ureido derivative with antitubercular properties. Spectrochim. Acta A 2021, 249, 119329 [ISSN 1386-1425, IF₂₀₁₉= 3.232]. https://doi.org/10.1016/j.saa.2020.119329
• Y. Sheena Mary, Y. Shyma Mary, Krátký M., Vinsova J., Baraldi C., Gamberini M.C. DFT, SERS-concentration and solvent dependent and docking studies of a bioactive benzenesulfonamide derivative. J. Mol. Struct. 2021, 1228 129680. [ISSN 0022-2860, IF₂₀₁₉ = 2.463]. https://doi.org/10.1016/j.molstruc.2020.129680
• Gamberinia M. C., Y.Shyma Mary, Y.Sheena Mary, Krátký M., Vinsova J., Baraldi C. Spectroscopic investigations, concentration dependent SERS, and molecular docking studies of a benzoic acid derivative. Spectrochim. Acta A 2021, 248, 119265 [ISSN 1386-1425, IF₂₀₁₉= 3.232]. https://doi.org/10.1016/j.saa.2020.119265

2020

• Krátký M., Baranyai Z., Štěpánková Š., Svrčková K., Švarcová M., Stolaříková J., Horváth L., Bősze S., Vinšová J. N-Alkyl-2-[4-(trifluoromethyl)benzoyl]hydrazine-1- carboxamides and Their Analogues: Synthesis and Multitarget Biological Activity. Molecules 2020, 25, 2268; https.//doi.org/10.3390/molecules25102268.  [ISSN 1420-3049, IF₂₀₁₉ = 3.267].
• Ambrożkiewicz W., Kučerová-Chlupáčová M., Janďourek O., Konečná K., Paterová P., Bárta P., Vinšová J., Doležal M., Zitko J. 5-Alkylamino-N-Phenylpyrazine-2-Carboxamides: Design, Preparation, And Antimycobacterial Evaluation. Molecules 2020, 25, 1561; https://doi.org/10.3390/molecules25071561 [ISSN 1420-3049, IF₂₀₁₉ = 3.267].
• Krátký M., Konečná K., Janoušek J., Brablíková M., Janďourek O., Trejtnar F., Stolaříková J., Vinšová J. 4-Aminobenzoic acid derivatives: Converting folate precursor to antimicrobial and cytotoxic agents. Biomolecules 2020, 10, 9, 1-21. doi:10.3390/biom10010009. [IF₂₀₁₉= 4,082].
• Krátký M., Jaklová K., Štěpánková Š., Svrčková K., Pflégr V., Vinšová J. N-[3,5-Bis(trifluoromethyl)phenyl]-5-bromo-2-hydroxybenzamide Analogues: Novel Acetyl- and Butyrylcholinesterase Inhibitors. Curr. Top. Med. Chem. 2020, 20(23), 2094-2105. https://doi.org/10.2174/1568026620666200819154722 [IF₂₀₁₉ = 3,218]
• Krátký M., Štěpánková Š., Brablíková M., Svrčková K. Švarcová M., Vinšová J. Novel Iodinated Hydrazide-hydrazones and their Analogues as Acetyl- and Butyrylcholinesterase Inhibitors. Curr. Top. Med. Chem. 2020, 20, (23), 2106-2117. https://doi.org/10.2174/1568026620666200819155503 [IF₂₀₁₉ = 3,218].

2019

• Krátký M., Štěpánková Š., Houngbedji Neto-Honorius, Vosátka R., Vorčáková K., Vinšová J. 2-Hydroxy-N-phenylbenzamides and their Esters Inhibit Acetylcholinesterase and Butyrylcholinesterase. Biomolecules 2019, 9, 698; doi:10.3390/biom9110698, [IF₂₀₁₉= 4,082]]
• Krátký M., Janďourek O., Baranyai Zs., Novotná E., Stolaříková J., Bősze S., Vinšová J. Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds. Eur. J. Med. Chem. 2019, 181, 111578 [ISSN 0223-5234, IF₂₀₁₉= 5.572].

2018

• Krátký M., Vorčáková K., Vinšová J., Štěpánková Š. Investigation of salicylanilide and 4-chlorophenol-based N-monosubstituted carbamates as potential inhibitors of acetyl- and butyrylcholinesterase, Bioorg. Chem. 2018, 80, 668-673 [ISSN 0968-0896, IF₂₀₁₇ = 3.929].
• Zitko J., Janďourek O., Paterová P., Navrátilová L., Kuneš J., Vinšová J., Doležal M. Design, synthesis and antimycobacterial activity of hybrid molecules combining pyrazinamide with 4-phenylthiazol-2-amine scaffold. MedChemComm. 2018. 9(4), 685-696. [ISSN 2040-2503], IF₂₀₁₇ = 2.342, doi: http://dx.doi.org/10.1039/C8MD00056E
• Pospíšilová Š., Michnová H., Pauk K., Vinšová J., Imramovský A., Čížek A., Jampílek J. In vitro activity of salicylamide derivatives against vancomycin-resistant enterococci. Bioorg. Med. Chem. Letters 2018, 28, 2184-2188. [ISSN 0960-894X, IF₂₀₁₇ = 2.442]
• Vosátka R., Krátký M., Švarcová M., Janoušek J., Stolaříková J., Madacki J., Husza  S., Mikušová K., Korduláková J.,Trejtnar F., Vinšová J. New lipophilic isoniazid derivatives and their 1,3,4-oxadiazole analogues: Synthesis, antimycobacterial activity and investigation of their mechanism of action. Eur. J. Med. Chem. 2018,151, 824-835. [ISSN 0223-5234, IF₂₀₁₇ = 4,816]
• Vosátka R., Krátký M., Vinšová J. Triclosan and its derivatives as antimycobacterial active agents Eur. J. Pharm. Sci. 2018, 114, 318–331. [ISSN 0928-0987, IF₂₀₁₆ = 3.466]. doi.org/10.1016/j.ejps.2017.12.013

2017

• Krátký M., Bősze S., Baranyai Zs., Stolaříková J., Vinšová J. Synthesis and biological evolution of hydrazones derived from 4-(trifluoromethyl)benzohydrazide. Bioorg. Med. Chem. Lett. 2017, 27,5185-5189. [ISSN 0960-894X, IF₂₀₁₆ = 2.454]. doi: 10.1016/j.bmcl.2017.10.050
• Krátký M., Dzurková M., Janoušek O., Konečná K., Trejtnar F., Stolaříková J., Vinšová J. Sulfadiazine Salicylaldehyde-Based Schiff Bases: Synthesis, Antimicrobial Activity and Cytotoxicity. Molecules 2017, 22, 1573 [ISSN 1420-3049, IF₂₀₁₆ = 2.861]. doi:10.3390/molecules22091573
• Krátký M., Stolaříková J., Vinšová J. Antimicrobial activity of rhodanine-3-acetic acid derivatives. Bioorg. Med. Chem. 2017, 25(6), 1839–1845 [ISSN 0968-0896, IF₂₀₁₆ = 2.930]. https://doi.org/10.1016/j.bmc.2017.01.045
• Baranyai Zs, Krátký M., Vosátka M., Szabó N., Senoner Sz., Dávid S., Stolaříková J., Vinšová J., Bősze S. In vitro biological evaluation of new antimycobacterial salicylanilide-tuftsin conjugates. Europ. J. Med. Chem. 2017, 133, 152-173 [ISSN 0223-5234, IF₂₀₁₆ = 4.519]. https://doi.org/10.1016/j.ejmech.2017.03.047
• Krátký M., Stolaříková J., Vinšová J. Novel Sulfamethoxazole Ureas and Oxalamides as Potential Antimicobacterial Agents. Molecules 2017, 22(4), 535 [ISSN 1420-3049, IF₂₀₁₆ = 2.861]. doi:10.3390/molecules22040535
• Krátký M., Vinšová J., Štěpánková Š., Vorčáková K., Navrátilová L., Trejtnar F., Stolaříková J. Novel Fluorophenylalanine Derivatives: Synthesis and Investigation of Their Biological Activity. Bioorganic Chemistry 2017, 71, 244 - 256 [ISSN: 0045-2068, IF₂₀₁₆ = 3.402]. https://doi.org/10.1016/j.bioorg.2017.02.010
• Paraskevopoulos G., Monteiro S., Vosátka R., Krátký M., Navrátilová L., Trejtnar F., Stolaříková J., Vinšová J. Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity. Bioorg. Med. Chem. 2017, 25(4), 1524-1532 [ISSN 0968-0896, IF₂₀₁₆ = 2.930]. http://dx.doi.org/10.1016/j.bmc.2017.01.016 

2016

• Krátký M.*, Štěpánková Š., Vorčáková K., Vinšová J. Synthesis and in vitro evaluation of novel rhodanine derivatives as potential cholinesterase inhibitors. Bioorganic Chemistry 2016, 68, 23-29  [ISSN 0045-2068, IF₂₀₁₆ = 3.231].
• Kozic J.*, Novák Z., Římal V., Profant V., Kuneš J., Vinšová J. Conformations, equilibrium thermodynamics and rotational barriers of secondary thiobenzanilides. Tetrahedron, 2016, 72, 2072-2083 [ISSN: 0040-4020, IF₂₀₁₆ = 2.651]. doi:10.1016/j.tet.2016.02.035
• Krátký M.*, Vinšová J. Salicylanilide N-monosubstituted carbamates: Synthesis and in vitro antimicrobial activity. Bioorg. Med. Chem. 2016, 24(6), 1322-1330. http://dx.doi.org/10.1016/j.bmc.2016.02.004   [ISSN 0968-0896, IF₂₀₁₅₆= 2.930].
• Krátký M.*, Štěpánková Š., Vorčáková K., Švarcová M, Vinšová J. Novel Cholinesterases Inhibitors Based on O-Aromatic N,N-Disubstituted Carbamates and Thiocarbamate, Molecules, 2016, 21, 191-201. [ISSN 1420-3049, IF₂₀₁₆ = 2.861].

• Krátký M.*, Vinšová J. Sulphur-Containing Heterocycles as Antimycobacterial Agents: Recent Advances in Thiophene and Thiadiazole Derivatives, Current Topics in Medicinal Chemistry, 2016, 16(26), 2921-2952 [ISSN 1389-4501, IF₂₀₁₆ = 2.561]. DOI: 10.2174/1568026616666160506131118

Development of new antituberculosis drugs

2022

• V. Finger, M. Kufa, O. Soukup, D. Castagnolo, J. Roh*, J. Korabecny.* Pyrimidine derivatives with antitubercular activity. Eur. J. Med. Chem. 2022, 15(246), 114946. (IF₂₀₂₁ = 7.088) (Q_AIS1)

2021

• N. Monakhova, J. Kordulakova, A. Vocat, A. Egorova, A. Lepioshkin, E. G. Salina, J. Nosek, E. Repkova, J. Zemanova, H. Jurdakova, R. Gorova, J. Roh, G. Degiacomi, J. C. Sammartino, M. R. Pasca, S. T. Cole, K. Mikusova, V. Makarov. Design and Synthesis of Pyrano[3,2-b]indolones Showing Antimycobacterial Activity. ACS Infect. Dis. 2021, 7(1), 88-100. (IF₂₀₁₉ = 5.084) (D_AIS1)

2019

• G. Karabanovich, J. Dušek, K. Savková, O. Pavliš, I. Pávková, J. Korabecny, T. Kučera, H. Kočová Vlčková, S. Huszár, Z. Konyariková, K. Konečná, O. Jandourek, J. Stolaříková, J. Korduláková, K. Vávrová, P. Pavek, V. Klimešová, A. Hrabalek, K. Mikušová, J. Roh*. Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-D-ribofuranose 2′-Oxidase. J. Med. Chem. 2019,62, 8115-8139. (IF₂₀₁₉ = 6.205) (Q1)

2017

• G. Karabanovich, J. Němeček, L. Valášková, A. Carazo, K. Konečná, J. Stolaříková, A. Hrabálek, O. Pavliš, P. Pávek, K. Vávrová, J. Roh,* V. Klimešová. S-Substituted 3,5-Dinitrophenyl 1,3,4-Oxadiazole-2-thiols and Tetrazole-5-thiols as Highly Efficient Antitubercular Agents. Eur. J. Med. Chem. 2017, 126, 369-383. (IF₂₀₁₆ = 4.519) (Q1)
• J. Němeček, P. Sychra, M. Macháček, M. Benková, G. Karabanovich, K. Konečná, V. Kavková, J. Stolaříková, A. Hrabálek, K. Vávrová, O. Soukup, J. Roh,* V. Klimešová. Structure-activity relationship studies on 3,5-dinitrophenyl tetrazoles as antitubercular agents. Eur. J. Med. Chem. 2017, 130, 419–432. (IF₂₀₁₆ = 4.519) (Q1)
• J. Roh *, G. Karabanovich, H. Vlčková, A. Carazo, J. Němeček, P. Sychra, L. Valášková, O. Pavliš, J. Stolaříková, V. Klimešová, K. Vávrová, P. Pávek, A. Hrabálek. Development of Water-Soluble 3,5-Dinitrophenyl Tetrazole and Oxadiazole Antitubercular Agents. Bioorg. Med. Chem. 2017, 25, 5468–5476.
• I. Melnikova, J. Roh, J. Kuneš, T. Artamonova, Y. Zevatskii, L. Myznikov. Non-catalyzed addition of heterocyclic thiols and 5-substituted-1H-tetrazoles to vinyl ethers. Tetrahedron Lett. 2017, 58, 3842–3845.

2016

• G. Karabanovich, J. Zemanová, T. Smutný, R. Székely, M. Šarkan, I. Centárová, A. Vocat, I. Pávková, P. Čonka, J. Němeček, J. Stolaříková, M. Vejsová, K. Vávrová, V. Klimešová, A. Hrabálek, P. Pávek, S. T. Cole, K. Mikušová, J. Roh.* Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-Oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. J. Med. Chem. 2016, 59, 2362−2380. (IF₂₀₁₆ = 6.259) (Q1)

 

Synthesis of dexrazoxane analogues and iron chelators

2022

• P. Haskova, L. Applova, H. Jansova, P. Homola, K. J. Franz, K. Vavrova, J. Roh, T. Simunek. Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine. Sci. Rep. 2022, 12, 9765. (IF₂₀₂₁ = 4.997) (Q_AIS2)

2021

• E. Jirkovský, A. Jirkovská, H. Bavlovič-Piskáčková, V. Skalická, Z. Pokorná, G. Karabanovich, P. Kollárová-Brázdová, J. Kubeš, O. Lenčová-Popelová, Y. Mazurová, M. Adamcová, A. R. Lyon, J. Roh, T. Šimůnek, P. Štěrbová-Kovaříková, M. Štěrba. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation. Circ Heart Fail. 2021;14: e008209. (IF₂₀₂₁ = 10.447) (D_AIS1)
• P. Kollárová-Brázdová, O. Lencova-Popelova, G. Karabanovich; J. Kocúrová-Lengvarská, J. Kubes, N. Váňová, Y. Mazurova, M. Adamcova, A. Jirkovska, M. Holečková, T. Šimůnek, P. Štěrbová-Kovaříková, J. Roh, M. Štěrba. Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity on a rabbit model in vivo. Clin. Sci. 2021. https://doi.org/10.1042/CS20210311. (IF₂₀₂₀ = 6.124) (Q_AIS1)
• A. Jirkovská, G. Karabanovich, J. Kubeš, V. Skalická, I. Melnikova, J. Korábečný, T. Kučera, E. Jirkovský, L. Nováková, H. Bavlovič Piskáčková, J. Škoda, M. Štěrba, C. A. Austin, T. Šimůnek, J. Roh*. Structure−Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions. J. Med. Chem. 2021, 64, 3997-4019. (IF₂₀₂₀ = 7.446) (D_AIS1)
• H. Bavlovič Piskáčková, H. Jansová, J. Kubeš, G. Karabanovich, N. Váňová, P. Kollárová-Brázdová, I. Melnikova, A. Jirkovská, O. Lenčová-Popelová, J. Chládek, J. Roh, T. Šimůnek, M. Štěrba, P. Štěrbová-Kovaříková. Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF 193 as potential cardioprotective agents against anthracycline cardiotoxicity. Scientific Reports. 2021 11, 4456. (IF₂₀₂₀ = 4.379) (Q_AIS1)

2020

• P. Kollárová-Brázdová, A. Jirkovská, G. Karabanovich, Z. Pokorná, H. Bavlovič Piskáčková, E. Jirkovský, J. Kubeš, O. Lenčová-Popelová, Y. Mazurová, M. Adamcová, V. Skalická, P. Štěrbová-Kovaříková, J. Roh, T. Šimůnek and M. Štěrba. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity. Journal of Pharmacology and Experimental Therapeutics 2020, 373(3), 402-415. (IF₂₀₁₉ = 3.561)  (Q2)

2019

• P. Reimerova, A. Jirkovska, H. Piskackova, G. Karabanovich, J. Roh, T. Simunek, P. Sterbova-Kovarikova. UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study.  Sci. Rep. 2019, 9, Art. No. 4524. (IF₂₀₁₉ = 3.998) (Q1)
• P. Reimerova; J. Stariat, H. Piskackova, H. Jansova, J. Roh, D.S. Kalinowski, M. Machacek, T. Simunek, D. R. Richardson, P. Sterbova-Kovarikova. Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials. Anal. Bioanal. Chem. 2019, 411(11), 2383-2394. (IF₂₀₁₉ = 3.637) (Q1)

2018

• H. Jansová, J. Kubeš, P. Reimerová, P. Štěrbová-Kovaříková, J. Roh*, and T. Šimůnek.* 2,6-Dihydroxybenzaldehyde Analogues of the Iron Chelator Salicylaldehyde Isonicotinoyl Hydrazone: Increased Hydrolytic Stability and Cytoprotective Activity against Oxidative Stress. Chem. Res. Toxicol., 2018, 31 (11), 1151–1163. (IF₂₀₁₇ = 3.432) (Q1)
• E. Jirkovský, A. Jirkovská, J. Bureš, J. Chládek, O. Lenčová, J. Stariat, Z. Pokorná, G. Karabanovich, J. Roh, P. Brázdová, T. Šimůnek, P. Kovaříková, M. Štěrba. Pharmacokinetics of the cardioprotective drug dexrazoxane and its active metabolite ADR-925 with focus on cardiomyocytes and the heart. Journal of Pharmacology and Experimental Therapeutics. 2018, 364 (3), 433-446. (IF₂₀₁₇ = 3.706) (Q1)

2017

• J. Bureš, A. Jirkovská, V. Šesták, H. Jansová, G. Karabanovich, J. Roh, M. Štěrba, T. Šimůnek, P. Kovaříková. Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite. Toxicology 2017, 392, 1-10.

2016

• V. Sestak, J. Stariat, J. Cermanova, E. Potuckova, J. Chladek, J. Roh, J. Bures, H. Jansova, P. Prusa, M. Sterba, S. Micuda, T. Simunek, D. S. Kalinowski, D. R. Richardson, P. Kovarikova. Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents. Oncotarget, 2016, 6 (40), 42411-42428. (IF₂₀₁₆ = 5.168) (Q1)
• V. Sestak , J. Roh, L. Klepalova, P. Kovarikova. A UHPLC-UV-QTOF Study on the Stability of Carfilzomib, A Novel Proteasome Inhibitor. Journal of Pharmaceutical and Biomedical Analysis, 2016, 124, 365–373. (IF₂₀₁₆ = 3.255) (Q1)
• H. Jansová, J. Bureš, M. Macháček, P. Hašková, A. Jirkovská, J. Roh, Q. Wang, K. J. Franz, P. Kovaříková, T. Šimůnek. Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products. Toxicology, 2016, 350, 15–24. (IF₂₀₁₆ = 3.582) (Q1)
• J. Roh,* G. Karabanovich, V. Novakova, T. Šimůnek, K. Vávrová. Large-scale synthesis of piperazine-2,6-dione and its use in the synthesis of dexrazoxane analogues. Synthesis. 2016, 48, 4580-4588. (IF₂₀₁₆ = 2.650)